Question · asked by 1 review
Rifampicin vs placebo: Proportion of participants with adverse events and severe adverse events
- Population
- guttate psoriasis
- Intervention
- Rifampicin
- Comparison
- placebo
- Outcome
- Proportion of participants with adverse events and severe adverse events
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Rifampicin vs placebo Proportion of participants with adverse events and severe adverse events · guttate psoriasis The review found no eligible studies for this question. Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.